Journal Article
. 2019 Jul;177(3).
doi: 10.1007/s10549-019-05346-1.

Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test

Susan K Boolbol 1 Manju Harshan 2 Manjeet Chadha 3 Laurie Kirstein 4 Jean-Marc Cohen 5 Paula Klein 6 Joseph Anderson 7 Deborah Davison 7 Debbie M Jakubowski 7 Frederick L Baehner 8 Stephen Malamud 6 
Affiliations
  • PMID: 31302854
  •     26 References
  •     2 citations

Abstract

Purpose: Adjuvant therapy decisions may in part be based on results of Oncotype DX Breast Recurrence Score® (RS) testing of primary tumors. When necessary, lymph node metastases may be considered as a surrogate. Here we evaluate the concordance in gene expression between primary breast cancers and synchronous lymph node metastases, based on results from quantitative RT-PCR-based RS testing between matched primary tumors and synchronous nodal metastases.

Methods: This retrospective, exploratory study included patients (≥ 18 years old) treated at our center (2005-2009) who had ER+ , HER2-negative invasive breast cancer and synchronous nodal metastases with available tumor blocks from both sites. Paired tissue blocks underwent RS testing, and RS and single-gene results for ER, PR, and HER2 were explored between paired samples.

Results: A wide distribution of RS results in tumors and in synchronous nodal metastases were modestly correlated between 84 paired samples analyzed (Pearson correlation 0.69 [95% CI 0.55-0.78]). Overall concordance in RS group classification between samples was 63%. ER, PR, and HER2 by RT-PCR between the primary tumor and lymph node were also modestly correlated (Pearson correlation [95% CI] 0.64 [0.50-0.75], 0.64 [0.49-0.75], and 0.51 [0.33-0.65], respectively). Categorical concordance (positive or negative) was 100% for ER, 77% for PR, and 100% for HER2.

Conclusions: There is modest correlation in continuous gene expression, as measured by the RS and single-gene results for ER, PR, and HER2 between paired primary tumors and synchronous nodal metastases. RS testing for ER+ breast cancer should continue to be based on analysis of primary tumors.

Keywords: Breast cancer; Genomics; Lymph node; Metastases; Oncotype DX®; Recurrence Score®.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Linda Sofie Lindström, Eva Karlsson, +6 authors, Jonas Bergh.
J Clin Oncol, 2012 Jun 20; 30(21). PMID: 22711854
Highly Cited.
Tumor heterogeneity: causes and consequences.
Andriy Marusyk, Kornelia Polyak.
Biochim Biophys Acta, 2009 Nov 26; 1805(1). PMID: 19931353    Free PMC article.
Highly Cited. Review.
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, +19 authors, College of American Pathologists.
J Clin Oncol, 2013 Oct 09; 31(31). PMID: 24101045
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Sunil S Badve, Frederick L Baehner, +13 authors, Joseph A Sparano.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487567
Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Jin-Ling Ba, Cai-Gang Liu, Feng Jin.
Asian Pac J Cancer Prev, 2014 Nov 26; 15(21). PMID: 25422206
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Hope S Rugo, R Bryan Rumble, +13 authors, Harold J Burstein.
J Clin Oncol, 2016 May 25; 34(25). PMID: 27217461
Highly Cited.
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
Eitan Amir, Naomi Miller, +9 authors, Mark Clemons.
J Clin Oncol, 2011 Nov 30; 30(6). PMID: 22124102    Free PMC article.
Highly Cited.
High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
David J Dabbs, Molly E Klein, +3 authors, Rohit Bhargava.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990395
Molecular heterogeneity in breast cancer: State of the science and implications for patient care.
Rachel E Ellsworth, Heather L Blackburn, +2 authors, Darrell L Ellsworth.
Semin Cell Dev Biol, 2016 Aug 30; 64. PMID: 27569190
Highly Cited. Review.
A gene expression signature that defines breast cancer metastases.
Rachel E Ellsworth, Jeff Seebach, +5 authors, Craig D Shriver.
Clin Exp Metastasis, 2008 Dec 30; 26(3). PMID: 19112599
Adjuvant therapy for breast cancer.
NIH Consens Statement, 2001 Aug 22; 17(4). PMID: 11512506
Review.
Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.
Xishan Hao, Baocun Sun, +11 authors, Wei Zhang.
Cancer, 2004 Mar 17; 100(6). PMID: 15022276
Molecular Concordance Between Primary Breast Cancer and Matched Metastases.
Anne Bruun Krøigård, Martin Jakob Larsen, Mads Thomassen, Torben A Kruse.
Breast J, 2016 Apr 19; 22(4). PMID: 27089067
Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.
S J Aitken, J S Thomas, +2 authors, D Faratian.
Ann Oncol, 2009 Oct 28; 21(6). PMID: 19858088
Occult primary breast cancer at a comprehensive cancer center.
Oluwadamilola M Fayanju, Donna B Jeffe, Julie A Margenthaler.
J Surg Res, 2013 Jul 31; 185(2). PMID: 23890400    Free PMC article.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.
T van Agthoven, M Timmermans, L C Dorssers, S C Henzen-Logmans.
Int J Cancer, 1995 Dec 11; 63(6). PMID: 8847135
Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2017 Jan 06; 67(1). PMID: 28055103
Highly Cited.
Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.
Gary V Walker, Grace L Smith, +7 authors, Thomas A Buchholz.
Cancer, 2010 Jun 22; 116(17). PMID: 20564117    Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effect of screening and adjuvant therapy on mortality from breast cancer.
Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534
Highly Cited.
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Frederick L Baehner, Ninah Achacoso, +5 authors, Laurel A Habel.
J Clin Oncol, 2010 Aug 11; 28(28). PMID: 20697093
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Anna-Karin Falck, Mårten Fernö, Pär-Ola Bendahl, Lisa Rydén.
World J Surg, 2010 Mar 10; 34(7). PMID: 20213203
Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients.
Yujie Lu, Yiwei Tong, +10 authors, Kunwei Shen.
Front Oncol, 2020 Aug 28; 10. PMID: 32850415    Free PMC article.
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Peng Qi, Yu Yang, +5 authors, Xiao-Yan Zhou.
Breast Cancer Res Treat, 2021 Jan 14;. PMID: 33439420    Free PMC article.